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A B S T R A C T
Oncolytic virus immunotherapy is rapidly gaining interest in the field of immunotherapy against cancer. The
minimal toxicity upon treatment and the dual activity of direct oncolysis and immune activation make therapy
with oncolytic viruses (OVs) an interesting treatment modality. The safety and efficacy of several OVs have been
assessed in clinical trials and, so far, the Food and Drug Administration (FDA) has approved one OV.
Unfortunately, most treatments with OVs have shown suboptimal responses in clinical trials, while they ap-
peared more promising in preclinical studies, with tumours reducing after immune cell influx. In several clinical
trials with OVs, parameters such as virus replication, virus-specific antibodies, systemic immune responses,
immune cell influx into tumours and tumour-specific antibodies have been studied as predictors or correlates of
therapy efficacy. In this review, these studies are summarized to improve our understanding of the determinants
of the efficacy of OV therapies in humans and to provide insights for future developments in the viro-im-
munotherapy treatment field.
1. Introduction
The development of cancer treatment has been, and still is, a
priority in the biomedical research community. The first effective
cancer treatments developed included surgery, radiotherapy and che-
motherapy, but given their limited use against some cancers, new
strategies are still being explored. Immunotherapy is one of the rela-
tively new strategies, in which the immune system is (re-) activated to
target and kill malignant cells. The use of immunotherapy to treat
cancer has gained substantial attention in the past decade and different
approaches have been developed to induce strong anti-tumour immune
responses, such as the use of cancer vaccines, adoptive T-cell transfer,
monoclonal antibodies against tumour antigens, checkpoint inhibitors
and oncolytic viruses (OVs). [1,2] Initially, OVs were explored to in-
duce direct oncolysis through virus replication in tumour cells or acti-
vation of the apoptosis pathway resulting in cell death, but more re-
cently it has become clear that activation of the immune system to
induce tumour cell death (indirect oncolysis), in which the viral in-
fection works as a kick-start to activate the immune system, may be
even more important. [3–5]
Numerous clinical and preclinical studies have reported promising
anti-tumour potential for viro-immunotherapy. Compared to che-
motherapies, less toxicities and adverse events were reported in clinical
trials with viro-immunotherapy, demonstrating the applicability of the
therapy. The reported mild adverse effects are often described as flu-
like symptoms. [6–8] Talimogene Laherparepvec (T-VEC/IMLYGIC), a
genetically modified herpes simplex virus expressing granulocyte
macrophage colony stimulating factor (GM-CSF), is the only OV that
has been successfully tested in phase III trials. The results from the
clinical trial resulted in the application of the therapy in the USA, EU
and Australia [9–11]. This application illustrates that viro-im-
munotherapy is suitable for implementation in daily clinical practice
[12,13].
However, while preclinical studies reported positive results, in-
cluding enhanced immunological anti-tumour responses, tumour
shrinkage and even complete clearance, viro-immunotherapy often re-
sulted in a poor anti-tumour efficacy in clinical trials. The approval for
only one OV to be used in viro-immunotherapy suggests that efficacy is
lost in translation from preclinical trials to the clinic. Determinants of
anti-tumour efficacy in murine models are often limited to increased
infiltration of T cells into the tumour. However, virological or im-
munological parameters to predict a positive response to treatment in
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clinical trials are scarcely evaluated and vary between studies.
Differences in administration strategies and clinical observations be-
tween studies make it difficult to draw conclusions on the efficacy of
different viro-immunotherapies. This review summarizes clinical out-
comes of several studies in relation to their corresponding administra-
tion strategies and reported parameters to improve our understanding
of the underlying determinants of an effective viro-immunotherapy.
2. Administration strategies
The safety and efficacy of several viro-immunotherapies have been
assessed in a number of Phase I clinical trials, including those using
adenovirus (AdV), herpes simplex virus (HSV), vaccina virus (VV),
measles virus (MV), parvovirus, Newcastle disease virus (NDV), re-
ovirus, and Seneca Valley virus (SVV) (summarized in Table 1). Results
from these studies demonstrated that the chosen strategies for admin-
istration influenced the virological and immunologic parameters and
even the safety and efficacy of the therapy.
2.1. Route, dosage and schedule of treatment affecting efficacy
Administration strategies vary in administration route, dosage and
schedule. In clinical trials, primarily intratumoral (I.T.) and intravenous
(I.V.) injections have been applied. I.T. administration has often been
preferred based on the assumption that I.T. administration, in contrast
to I.V. injection, provided a better control of viral distribution, in-
creased virus concentrations within the tumour and hence a better
therapeutic effect. In two cohort studies with AdV (Enadenotucirev)
[14] and Parvovirus (ParvOryx) [15], for treatment of resectable pri-
mary tumours or primary glioblastoma multiforme, the I.T. route and
I.V. route were directly compared. In these studies, viral DNA was
found in the tumours independent of the administration route, sug-
gesting that I.V. administration can result in successful targeting of
primary and even metastatic tumour tissues. This suggestion is further
supported by similar observations in other I.V. injection based studies
using VV (Pexa-Vec, vvDD) [16,17], reovirus (Reolysin) [18,19] and
SVV (SVV-001) [16,19,20]. While I.V. injected viruses infected primary
tumours as effective as metastatic tumours, I.T. administrated HSV
(Oncovex) also infected metastatic lesion, indicating subsequent sys-
temic spread of the virus upon I.T. administration [21]. The results of
these studies suggest that differences in administration routes do not
substantially affect viral spreading. However, no direct comparison of
overall survival between I.V. and I.T. administration has been made yet
in clinical trials to show the effect of different administration routes on
treatment efficacy. In addition to the administration routes, different
dosages and schedule options have been investigated in phase I and II
trials. Studies using oncolytic AdV (ICOVIR-5) or VV (Pexa-Vec) de-
monstrated that the use of a higher dosage improved the overall re-
sponse rate significantly compared to low dosages. [22,23] Similar re-
sults were reported in two studies, respectively with AdV and HSV, in
which treatment with serial dosages was compared to single treatment
[24,25]. Thus, the use of higher dosages and/or serial treatment sche-
dules improved efficacy compared to a single low dosage without af-
fecting adverse events in the patients of these studies.
2.2. Administration strategy affecting adverse events
The route, dosage or schedule of treatments do not only influence
the efficacy, but are also expected to have an effect on adverse effects
and thus patient’s health. Most clinical trials reported adverse events
ranging from grade I to III and occasionally grade IV (Table 1), but
there was no direct evidence that the administration strategy directly
affected these events. Initially, the I.T. route was considered the safest
route, as this route would provide more control over viral distribution,
reducing systemic viral recognition and hence should result in less
adverse events. However, this assumption did not always hold true for
every OV. The two cohort studies using AdV (Enadenotucirev) [14] and
Parvovirus (ParvOryx) [15], directly comparing the I.T. and I.V. route,
reported no additional toxicities due to I.V administration compared to
I.T administration [24,25]. Similar to I.V. administration, higher do-
sages were thought to result in more adverse events compared to using
low dosage. However, this correlation was not found in studies in which
patients with melanoma or liver tumours were treated with AdV
(ICOVIR-5) and VV (Pexa- Vec), where treatment with high and low
dosages were compared [22,23]. In addition, dose-escalation studies
with OVs such as SVV (NTX010) and reovirus (Reolysin), have de-
monstrated that for those OVs adverse effects were not dose dependent
[26,27]. Although these studies suggest that the use of high dosage or
serial dosages does not necessarily result in increased severe adverse
effects, these parameters need to be evaluated for each OV, to improve
therapy efficacy and prevent adverse events.
Short-term elevation in cytokine levels, such as IL-6, TNF-α and IFN-
γ, upon viro-immunotherapy correlated with adverse events and the
administration regimen could affect this type of adverse effects.
[16,22,28,29] For example, one patient had high levels of IL-6 (200 pg/
mL) upon I.V. injection with AdV (ICOVIR-5), which was found to ac-
count for the occurrence of the grade III adverse events that this person
accrued. [27] In another study, grade I-II acute flu-like symptoms were
associated with post-treatment elevation of IL-6 and IL-8 levels, which
rose after I.V. inoculation of poxvirus (vvDD) [17]. To lower these se-
vere adverse effects, longer infusion times or desensitization steps have
been evaluated in different studies. In a study with NDV (PV701), the
use of bolus dosing resulted in severely elevated cytokine levels and
high frequency of adverse effects [30]. In contrast, in a different phase I
trial, one hour infusion with the same virus resulted in only minor
elevations of TNF and IFN-α expression levels [31]. Similarly, the use of
a two-step desensitization strategy, with a smaller dosage followed by
an higher dosage, reduced the occurrence of high-grade adverse events
[32]. The reduction of adverse events after multiple cycles was also
observed in patients treated with oncolytic reovirus [33]. The results of
these studies suggest that adverse events are, at least in these clinical
trials, temporary and linked to the start of therapy. Unfortunately, none
of the studies using the different strategies with NDV (PV701) in-
vestigated the effect of the reduced induction of cytokine production on
efficacy of the therapy. Several other studies have shown a beneficial
effect of increased cytokine levels on therapy efficacy [34]. Future
studies should evaluate the effect of administration strategies on cyto-
kine responses, adverse effects and therapy efficacy.
3. Determinants of efficacy: virological and immunological
parameters
The direct oncolysis induced by OVs and the indirect effects of the
activated immune system influence various virological and im-
munological parameters. In clinical trials, these parameters consist of
anti-viral antibodies, virus replication, systemic immune responses,
immune cell influx and anti-tumour antibodies.
3.1. Anti-viral antibodies
Upon OV therapy, the immune system responds to the virus by
producing antiviral antibodies, including neutralizing antibodies,
which could affect the efficacy of viro-immunotherapy. In a study using
AdV (Onyx-015), pre-existing neutralizing antibodies against AdV were
associated with lower efficacy. [35] To avoid this neutralizing effect,
animal viruses, such as SVV or NDV, were considered more beneficial as
treatment modality in viro-immunotherapy. However, the presence of
neutralizing antibodies did not seem to effect viral replication in clin-
ical trials using oncolytic Reovirus and HSV [36,37]. Adair et al. and
Roulstone et al. demonstrated that reovirus used virus neutralizing
antibodies bound by monocytes to target tumours, indicating that these
neutralizing antibodies did not necessarily limit viral distribution
J.F. de Graaf, et al. Cytokine and Growth Factor Reviews xxx (xxxx) xxx–xxx
5
[18,38]. In addition, in a dose-escalation study with oncolytic HSV
(OncoVEX) pre-existing antibodies reduced adverse events, as in ser-
onegative patients, toxicities seemed to be more frequent compared to
patients with pre-existing immunity [24]. The induction of an early
antibody response was associated with a complete response of one
patient who was treated with oncolytic NDV (HUJ) [39]. A similar
observation was made in a study with oncolytic VV (Pexa-Vec) in which
responding patients had an increased antibody response compared to
non-responders [40]. These studies suggest that an anti-viral immune
response could be a predictive parameter for treatment efficacy. How-
ever, in studies using the FDA approved HSV (T-VEC) [24], NDV
(PV701) [32] or HSV (NV2010) [41], no correlation was observed be-
tween increased antiviral antibody titers and efficacy. Therefore, fur-
ther investigations are necessary to understand the effects of the in-
duction of antiviral antibodies and the potential correlation with
efficacy of the therapies.
3.2. Virus replication
In principle, the efficacy of viro-immunotherapy is based on virus
induced oncolysis and stimulation of the anti-tumour immune response.
Direct oncolysis is a result of virus replication in tumour cells, which
thus could be an important determinant of efficacy. Several studies
have reported the presence of viral genomes, proteins or even infectious
virus in tumour tissues. [15,17,48,22,33,42–47] In some studies, in-
fectious virus was even detected in the tumour of patients 130 days
after treatment with NDV (HUJ) and viral antigens 318 days after
treatment with HSV (HF10) after the start of therapy [36,49]. Also in
studies with the FDA approved HSV (T-VEC) [13], virus replication in
tumour tissues was observed. However, the contribution of virus re-
plication in the tumour to therapeutic efficacy is uncertain due to the
lack of correlative evidence on efficacy in clinical studies. For instance,
no correlation was observed between virus detection in tumours and
the response to treatments with MV (MV-CEA) [44] or VV (JX-594)
[46]. Therefore, the contribution of the direct oncolytic effect by virus
replication and the indirect oncolytic effects induced by the immune
system still needs to be established.
3.3. Immune cell influx
Induction of an antitumour immune response is one of the most
important objectives in clinical trials with immune therapies and can be
divided in local and systemic responses. Viro-immunotherapy studies
have shown that increased infiltration of cytotoxic T- and B-cells into
the tumour is indicative for positive patient responses. For example,
tumour influx of immune cells was observed in both a responding and a
non-responding patient after treatment with NDV (PV701). [30] The
tumour tissue of the responding patient contained lymphoid follicles
with germinal centers consisting of infiltrated immune cells. However,
the tumour tissue of the non-responding patient had multiple areas of
necrosis and inflammatory mononuclear infiltrating cells. Furthermore,
in a study comparing administration of serial versus single dosage of
AdV (CGT-102) in a cohort of patients with different types of tumours,
an increased T-cell infiltration was found after serial treatment, which
was not observed after single treatment [25]. This serial treatment re-
sulted in a median overall survival of 269 days versus 128 days in the
single treatment group and suggested the beneficial effects of the tu-
mour infiltration of immune cells. Similar observations were made in a
study with the FDA approved HSV (T-VEC) in which low counts of T
helper and cytotoxic T cells in blood and tumours correlated with dis-
ease progression [50,51]. Therefore, tumour infiltration of T cells re-
mains one of the most important objectives of viro-immunotherapy,
which has often been demonstrated in preclinical models, but is not
always achieved in clinical trials.
In addition to inducing T cell infiltrations, the reduced presence of
immune suppressive regulatory T cells (Tregs) in tumours is considered
a prognostic value for survival of cancer patients in general. [52] For
instance, in a phase I study with HSV (T-Vec) for patients with mel-
onama, reduced Tregs infiltration was observed into the tumours [50].
In addition, in a study using AdV (Ad5/3-D24-GMCSF) in combination
with cyclophosphamide, patients treated with only the virus or only
with cyclophosphamide had less Tregs in their tumours compared to
patients treated with combination therapy [53]. Improved clinical
outcomes were reported for the patients receiving the combination
therapy, but a correlation with the decreased Tregs levels was not
mentioned. Thus, the importance of reduced amounts of Tregs in tu-
mour tissues as an objective in clinical trials should be further in-
vestigated.
3.4. Systemic immune responses
The potential prognostic determinants of efficacy upon treatment
could perhaps most easily be determined by evaluation of the systemic
immune responses upon treatment. Studies conducting blood analyses
often demonstrated that patients did respond systemically to the
therapy by having short-term and/or long-term elevated cytokine levels
and/or increased immune cell counts (Table 1). In case of short-term
elevated cytokine levels, such as those of IL-6, IL-8 and TNF-α, it was
already mentioned that this increased the prevalence of adverse effects,
but little is known about the influence on treatment efficacy. In addi-
tion to short-term elevated cytokine levels, long-term elevated cyto-
kines levels, such as those of IL-2, IL-10 and IFN-γ, are also often ob-
served. For instance, in patients treated with serial dosages of AdV
(CGTG-102), long-term elevation of IL-10 levels was observed and an
improved overall survival was reported in patients treated with a serial
dosage in contrast to patients treated with a single dosage. However, a
correlation between increased long-term cytokine levels and survival
was not investigated in detail. [25] Similarly, increased counts of
granulocytes, such as neutrophils and eosinophils, and cytotoxic
(CD8+) and helper T (CD4+) cells upon viro-immunotherapy are often
observed, but potential correlations have not been investigated.
[43,50,51,54,55] Thus, the effect of systemic immune responses on
overall survival remains to be evaluated as prognostic value for treat-
ment efficacy.
3.5. Tumour-associated antigen specific antibodies
Another important systemic immune response is the production of
tumour-associated antigen specific antibodies (TAA-Ab), which are
produced by B cells and can induce antibody dependent cellular cyto-
toxicity by NK cells. However, B cells themselves are often negatively
associated with tumour development, because they secrete pro-tu-
mourigenic factors and immune suppressive cytokines. [56] In addition,
the expression of TAA-Abs often correlates with decreased overall sur-
vival in cancer patients [57]. For example, patients that responded to
treatment with ADV (CGTC-602) displayed decreased antibody titers
against tumour antigens CEA, NY-ESO-1, survivin and MUC-1, whereas
anti-tumour T cell responses were increased [58]. These results suggest
that inhibition of B cell responses could be important for an effective
therapy and reduced TAA production upon treatment could be a good
prognostic value for the efficacy of viro-immunotherapy.
4. Future perspectives
Viro-immunotherapy therapy is establishing itself as an im-
munotherapy. However, in clinical trials, the overall responses have
often been limited, whereas in preclinical trials the therapy looked
promising. Apparently, the efficacy of the new therapy is lost in
translation from murine to human studies in which observations made
in preclinical trials, such as T cell infiltrations, are lacking in clinical
trials. To improve our understanding about prognostic parameters of
effective therapies in humans, we summarized different study outcomes
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and their findings.
Several virological and immunological parameters have been re-
ported, including cytokine levels, virus replication, (pre-existing) virus
neutralizing antibodies, TAA-Abs and influx of immune cells. While
some of these parameters have been infrequently monitored, others
were extensively examined but without reporting any clear correlation
with efficacy of the therapy. Opinions on the value of some of these
observations as determinants of efficacy have been subject to change,
such as the presence of pre-existing virus neutralizing antibodies.
Against expectations, these antibodies were shown to improve rather
than limit virus distribution in most treatments. Slowly, preclinical
studies are showing benefits of pre-existing anti-viral antibodies. [59]
The increased knowledge on the potential positive role of pre-existing
antibodies resulted in exploiting this in viro-immunotherapy through
vaccinating patients before treatment [60].
This newly gained insight in the role of virus neutralizing antibodies
emphasises the need to obtain more in-depth knowledge on distinct
immunologic parameters in order to characterize different determi-
nants of efficacy to improve the successful translation of preclinical
studies to clinical trials of viro-immunotherapy.
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